Previous 10 | Next 10 |
– Consistent Scientific Leadership Focused on Sustainable Innovation – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President. Dr. Vaishnaw joined A...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 40 th Annual J.P. Morgan Healthcare Conference, being held virtually, on Monday, January 10, 2022 at 9:45 am ET. This prese...
BridgeBio Pharma (NASDAQ:BBIO) perks up 3% premarket after shedding around 72% during yesterday's intrady session after its late-stage study for acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint. Following this news, sever...
Gainers: PyroGenesis Canada (NASDAQ:PYR) +72%. Microbot Medical MBOT +50%. CollPlant Biotechnologies CLGN +32%. Future FinTech FTFT +41%. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. Spruce Biosciences (NASDAQ:SPRB) +31%. Tarena International TEDU +19%. CNF...
Gainers: Microbot Medical (NASDAQ:MBOT) +51%, CollPlant Biotechnologies (NASDAQ:CLGN) +27%, Lucira Health (NASDAQ:LHDX) +14%, IceCure Medical (NASDAQ:ICCM) +13%, Cue Health (NASDAQ:HLTH) +12%. Losers: BridgeBio Pharma (NASDAQ:BBIO) -71%, Biond...
The FDA has approved Leqvio (inclisiran) — developed by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Novartis (NYSE:NVS) — to lower low-density lipoprotein cholesterol. In the U.S., Leqvio is the fourth small interfering RNA (siRNA) therapy and the first indicated to reduce lipopro...
– Leqvio ® Becomes Fourth RNAi Therapeutic Approved by U.S. FDA and First and Only for Lowering LDL-C in Atherosclerotic Cardiovascular Disease (ASCVD) Which Can Affect Up to 30 Million Americans – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the ...
Alnylam Pharmaceuticals (ALNY -5.0%) is trading lower despite the company’s newly announced plans to begin an early-stage study for its Alzheimer’s disease (AD) candidate, ALN-APP. Cambridge, Massachusetts-based Alnylam (NASDAQ:ALNY), focused on RNAi therapeutics, has already su...
- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer’s Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry’s First-Ever RNAi Therapeutic Program for CNS Disease and Represents the Start of Aln...
– Annual progress report highlights the breadth of innovative and collaborative initiatives that support accessibility of RNAi therapeutics for people who can benefit worldwide – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics co...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...